A comprehensive analysis was conducted to evaluate potential biases and diagnostic efficacy in demographic and clinicopathological characteristics, including age, gender, and tumor stage, of the Vimentin/POU4F2 combined methylation panel in urine DNA. This evidence concerns the gene VIM and neoplasm.